Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Northwestern University
Study ID
NCT01259089
Phase
PHASE1/PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • erlotinib hydrochloride — DRUG
    Given orally
  • Hsp90 inhibitor AUY922 — DRUG
    Given IV
  • laboratory biomarker analysis — OTHER
    Correlative studies
  • needle biopsy — PROCEDURE
    Undergo image-guided needle biopsy (correlative studies)
  • mutation analysis — GENETIC
    Correlative studies
  • pharmacological study — OTHER
    Correlative studies

Study Details

Hsp90 inhibitor AUY922 and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase I/II trial is studying the side effects and best dose of Hsp90 inhibitor AUY922 when given together with erlotinib hydrochloride and to see how well it works in treating patients with stage IIIB-IV non-small cell lung cancer.

Key Dates

First listed
Dec 13, 2010
Start date
Apr 27, 2011
Status verified
Oct 2018
Primary completion
Jun 4, 2013
Completion
Sep 29, 2014

Study Design

Enrollment
38 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm I
    Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Maximally Tolerated Dose (MTD) of AUY922 and Erlotinib Treatment Combination (Phase I) [ Time Frame: During the first 4 weeks of treatment for each patient. ]

Locations (2)

FacilityCityStateZIPSite coordinators
Northwestern UniversityChicagoIllinois60611-
Memorial Sloan-Kettering Cancer CenterNew YorkNew York10065-

Find similar trials in Chicago, IL

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Northwestern University· Chicago, ILMemorial Sloan-Kettering Cancer Center· New York, NY

Related Studies